Hemoglobin promotes Aβ oligomer formation and localizes in neurons and amyloid deposits

The objective of this study was to search for brain-specific binding proteins that participated in Abeta aggregation. Immunoprecipitation of Abeta in Alzheimer's brain homogenate revealed a major co-precipitating 16-kDa protein band, which was identified through mass spectrometry as hemoglobin (Hb) alpha and beta chains. Hemoglobin was distributed in Alzheimer's disease (AD) patients in a brain region-dependent manner, with the highest levels in the hippocampus and parietal gray (PG) matter, followed by parietal white matter (PW), and the lowest in cerebellum (Cb). AD parietal gray and white matters exhibited higher Hb levels than those in the nondemented (ND) group. Likewise, RT-PCR revealed that the Hb mRNA levels in AD inferior temporal gyri were higher than those of ND subjects. Furthermore, Hb was shown to promote Abeta oligomer formation. Immunohistochemical studies indicated that Hb was localized within the cytosol of pyramidal neurons in the hippocampus, suggesting a potential source of intracerebral Hb. Finally, double immunofluorescent assay confirmed the co-localization of Hb with senile plaques (SP) and cerebral amyloid angiopathy (CAA). We propose that an elevation in brain Hb via circulation leakage or perturbations of Hb gene regulation may participate in AD pathogenesis.

[1]  S. V. van Duinen,et al.  Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[2]  Mark A. Smith,et al.  Iron: A Pathological Mediator of Alzheimer Disease? , 2002, Developmental Neuroscience.

[3]  D. Price,et al.  Differential expression of amyloid precursor protein mRNAs in cases of Alzheimer's disease and in aged nonhuman primates , 1990, Neuron.

[4]  G. Campbell,et al.  Increased levels of hemoglobin-derived and other peptides in Alzheimer's disease cerebellum , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[5]  E. Matsubara,et al.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  V. Ivanov,et al.  Isolation of endogenous hemorphin-related hemoglobin fragments from bovine brain. , 1994, Biochemical and biophysical research communications.

[7]  A. Roses,et al.  Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. , 1994, The Journal of clinical investigation.

[8]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[9]  P. Mantyh,et al.  Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.

[10]  W. Strittmatter,et al.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Titani,et al.  Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. , 2000, Biochimica et biophysica acta.

[12]  K. Titani,et al.  Differential Expression of β Amyloid Protein Precursor (APP) and tau mRNA in the Aged Human Brain: Individual Variability and Correlation between APP‐751 and Four‐Repeat tau , 1991, Journal of neuropathology and experimental neurology.

[13]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[14]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M J Ball,et al.  Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. , 1993, The Journal of biological chemistry.

[16]  P. Lansbury,et al.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[18]  T. Wisniewski,et al.  Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. , 1994, Biochemical and biophysical research communications.

[19]  D. Anderson,et al.  Neuronophagia by Leukocytes in Experimental Spinal Cord Injury , 1983, Journal of neuropathology and experimental neurology.

[20]  T Vogel,et al.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. , 1994, The American journal of pathology.

[21]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[22]  H. Hamazaki.  Amyloid P Component Promotes Aggregation of Alzheimer′s β-Amyloid Peptide , 1995 .

[23]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[24]  L. Lannfelt,et al.  Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Verhaert,et al.  Identification of two‐dimensionally separated human cerebrospinal fluid proteins by N‐terminal sequencing, matrix‐assisted laser desorption/ionization — mass spectrometry, nanoliquid chromatography‐electrospray ionization‐time of flight‐mass spectrometry, and tandem mass spectrometry , 2000, Electrophoresis.

[26]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Jellinger.  Vascular-ischemic dementia: an update. , 2002, Journal of neural transmission. Supplementum.

[28]  B. Dahlbäck,et al.  Inhibition of Alzheimer β-Peptide Fibril Formation by Serum Amyloid P Component (*) , 1995, The Journal of Biological Chemistry.

[29]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[30]  Ashley I. Bush,et al.  Redox-active iron mediates amyloid-β toxicity , 2001 .

[31]  J. Eaton,et al.  Hemoglobin. A biologic fenton reagent. , 1984, The Journal of biological chemistry.

[32]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[33]  K. Titani,et al.  β‐Amyloid Protein Precursor and τ mRNA Levels Versus β‐Amyloid Plaque and Neurofibrillary Tangles in the Aged Human Brain , 1993 .

[34]  J. Rogers,et al.  Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. , 1997, The American journal of pathology.

[35]  J. C. Torre.  Impaired Cerebromicrovascular Perfusion: Summary of Evidence in Support of Its Causality in Alzheimer's Disease , 2000 .

[36]  R. Faull,et al.  Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process , 2001, Proteomics.

[37]  T. Foster,et al.  Gene Microarrays in Hippocampal Aging: Statistical Profiling Identifies Novel Processes Correlated with Cognitive Impairment , 2003, The Journal of Neuroscience.

[38]  J. C. Torre,et al.  Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .

[39]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[40]  J W Eaton,et al.  Hemoglobin potentiates central nervous system damage. , 1987, The Journal of clinical investigation.

[41]  D. Selkoe.  Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[42]  P. Fraser,et al.  α1‐Antichymotrypsin Binding to Alzheimer Aβ Peptides Is Sequence Specific and Induces Fibril Disaggregation In Vitro , 1993 .

[43]  P. Cutler,et al.  The recognition of haemoglobin by antibodies raised for the immunoassay of β‐amyloid , 1997, FEBS letters.

[44]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[45]  P. Fraser,et al.  An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar aβ-amyloid in rat brain , 1994, Neuron.

[46]  M. Emmerling,et al.  Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. , 1997, Biochemical and biophysical research communications.

[47]  V. Anderson,et al.  Hypohaptoglobinemia associated with familial epilepsy , 1985, The Journal of experimental medicine.